Home » Sumavel DosePro, Levadex to Earn About $400 Million in Combined Sales by 2018
Sumavel DosePro, Levadex to Earn About $400 Million in Combined Sales by 2018
Decision Resources … finds that Zogenix/Astellas Pharma/Desitin Pharmaceuticals’ needle-free Sumavel DosePro, which launched earlier this
month in the United States, and MAP Pharmaceuticals’ orally-inhaled Levadex will earn approximately $400 million in combined sales by 2018 in the
migraine drug market.
StreetInsider
StreetInsider
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May